Sugi Predict

Sugi Predict / Compounds / Neuropeptide-Y

Neuropeptide-Y

Neuropeptide-Y

SCHEMBL3051623

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)[C@@H](C)CC

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ NPY2R P49146 11/20 0.82
▸ NPY1R P25929 10/20 0.82
▸ NPY4R P50391 8/20 0.82
▸ NPY5R Q15761 8/20 0.82
▸ TFPI P10646 5/20 0.74
▸ RAMP3 O60896 1/20 0.72
▸ CALCR P30988 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Human Neuropeptide Y SCHEMBL29780330 0.98 NPY2R (0.79) NPY2RNPY1RNPY4RNPY5RTFPI
SCHEMBL29399759 0.95 NPY2R (0.89) NPY2RNPY1RNPY4RNPY5RTFPI
SCHEMBL30121639 0.94 NPY2R (0.92) NPY2RNPY1RNPY4RNPY5RTFPI
Neuropeptide-Y SCHEMBL31042464 0.94 NPY2R (0.73) NPY2RNPY1RNPY4RNPY5RTFPI
Human Neuropeptide Y SCHEMBL29523253 0.92 NPY2R (0.70) NPY2RNPY1RNPY4RNPY5RTFPI
Human Neuropeptide Y SCHEMBL29523348 0.91 CALCR (0.72) NPY2RNPY1RNPY4RNPY5RCALCR
SCHEMBL29496288 0.91 NPY2R (0.74) NPY2RNPY1RNPY4RNPY5RTFPI
SCHEMBL29571016 0.89 NPY2R (0.70) NPY2RNPY1RNPY4RNPY5RCALCR
SCHEMBL29436010 0.89 NPY2R (0.77) NPY2RNPY1RNPY4RNPY5RTFPI
SCHEMBL30735721 0.89 NPY2R (0.77) NPY2RNPY1RNPY4RNPY5RTFPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3532092-B1 IMMUNOGLOBULINS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2026-04-29 — — EP claimed
EP-4271674-B9 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2026-03-11 — — EP claimed
EP-4271672-B1 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-12-03 — — EP claimed
EP-4271674-B3 CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-12-03 — — EP claimed
WO-2025229624-A2 NEW CD38 INHIBITORS NAPA THERAPEUTICS LIMITED (GB) 2025-11-06 — — WO claimed
US-20250339483-A1 EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF AGS THERAPEUTICS SAS (FR) 2025-11-06 — — US claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 — — US claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 — — EP claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 — — EP claimed
EP-4192831-B1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2025-10-22 — — EP claimed
EP-4323393-A1 PANCREATIC ISLET ORGANOIDS AS PROTEIN FACTORIES BioCrine AB (SE) 2024-02-21 — — EP claimed
CN-117460740-A Islet organoids as protein factories 拜欧凯瑞尼公司 2024-01-26 — — CN claimed
WO-2022218876-A1 PANCREATIC ISLET ORGANOIDS AS PROTEIN FACTORIES BIOCRINE AB (SE) 2022-10-20 — — WO claimed
US-20100323963-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF AETERNA ZENTARIS GMBH (DE) 2010-12-23 — — US claimed
US-20100317580-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF AETERNA ZENTARIS GMBH (DE) 2010-12-16 — — US claimed
CN-101578287-A Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazoles derivatives, process for their preparation and their use AETERMA ZENTARIS GMBH (DE) 2009-11-11 — — CN claimed
EP-2066679-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF AEterna Zentaris GmbH (DE) 2009-06-10 — — EP claimed
US-20080090758-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF AETERNA ZENTARIS GMBH (DE) 2008-04-17 — — US claimed
EP-1900742-A1 Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof AEterna Zentaris GmbH (DE) 2008-03-19 — — EP claimed
WO-2008028934-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF AETERNA ZENTARIS GMBH (DE) 2008-03-13 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339483-A1 EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR BIODISTRIBUTION UPON INTRANASAL ADMINISTRATION, AND USES THEREOF NLN, DCX, CNTN1 NPY2R 1189/4885NPY1R 952/4885NPY4R 817/4885
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES FCGR2A, FCGR3B, FCGR1A NPY2R 3644/4885NPY1R 3936/4885NPY4R 4341/4885
US-20100323963-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF EPCAM, CD99, PTMS NPY2R 2770/4885NPY1R 2259/4885NPY4R 1258/4885
US-20100317580-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF EPCAM, CD99, PTMS NPY2R 2770/4885NPY1R 2259/4885NPY4R 1258/4885
US-20080090758-A1 CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF EPCAM, CD99, PTMS NPY2R 2770/4885NPY1R 2259/4885NPY4R 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.